This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Antithrombotic/Anticoagulant Drugs: World Market 2012-2022

Table 4.2 Leading National Markets: Forecasts ($bn), 2010-2022

Table 4.3 Antithrombotic/Anticoagulant Drug Market Shares (%) by Country, 2012 & 2022

Table 4.4 US Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.5 Japanese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.6 Leading European Antithrombotic/Anticoagulant Drug Market Forecasts ($bn), 2010-2022

Table 4.7 Chinese Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 4.8 Indian Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Table 5.1 Leading Antithrombotic/Anticoagulant Drugs: Sales ($m) and Market Shares (%), 2010

Table 5.2 Leading Antithrombotic/Anticoagulant Drugs: Forecasts ($m), 2010-2022

Table 5.3 Plavix Sales Forecast ($m), 2010-2022

Table 5.4 Lovenox Sales Forecast ($m), 2010-2022

Table 5.5 Pletal Sales Forecast ($m), 2010-2022

Table 5.6 Fragmin Sales Forecast ($m), 2010-2022

Table 5.7 Asasantin Sales Forecast ($m), 2010-2022

Table 5.8 Arixtra Sales Forecast ($m), 2010-2022

Table 5.9 Aspirin Cardio Sales Forecast ($m), 2010-2022

Table 5.10 Opalmon Sales Forecast ($m), 2010-2022

Table 5.11 Angiomax Sales Forecast ($m), 2010-2022

Table 5.12 Activase Sales Forecast ($m), 2010-2022

Table 5.13 Newly Launched Drugs, 2009-2011

Table 5.14 Effient Sales Forecast ($m), 2010-2022

Table 5.15 Pradaxa Sales Forecast ($m), 2011-2022

Table 5.16 Brilinta Sales Forecast ($m), 2011-2022

Table 5.17 Xarelto Sales Forecast ($m), 2011-2022

Table 6.1 Platelet Aggregation Inhibitors: R&D Pipeline, 2011

Table 6.2 Heparin Drugs: R&D Pipeline, 2011

Table 6.3 Fibrinolytics: R&D Pipeline, 2011

Table 6.4 Direct Thrombin Inhibitors: R&D Pipeline, 2011

Table 6.5 Direct Factor Xa Inhibitors: R&D Pipeline, 2011

Table 6.6 R&D Pipeline for Other Antithrombotic Agents, 2011

Table 7.1 SWOT Analysis, 2012-2022

Table 7.2 STEP Analysis, 2012-2022

Table 9.1 World Market Forecast ($bn), 2010-2022

 

List of Figures

 

Figure 3.1 Antithrombotic/Anticoagulant Drug Market Forecast ($bn), 2010-2022

Figure 3.2 Leading Antithrombotic/Anticoagulant Therapeutic Classes: Market Shares (%), 2010

Figure 3.3 Leading Therapeutic Class Forecast: Market Shares (%), 2012

Figure 3.4 Leading Therapeutic Class Forecast: Market Shares (%), 2022

Figure 3.5 Platelet Aggregation Inhibitors: Market Forecast ($bn), 2010-2022

6 of 8

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs